HOOK (hookipapharma.com) Total Enterprise Value

hookipapharma.com - graphic logo of issuer HOOK

This chart of HOOKIPA Pharma Inc. (HOOK) market value demonstrates a figure of . The company's revenues are based on the development of immunotherapy, receiving funds from strategic partners and future sales of the Vaxwave platform. Growth is driven by research in the fields of HIV and oncology. Meanwhile, the enterprise strictly adheres to environmental standards, guaranteeing the safe disposal of biomaterials and the cleanliness of its laboratories.

HOOK (HOOKIPA Pharma, Inc.) Total Company Value history from 07/04/2022 to 10/28/2026

HOOKIPA Pharma (HOOK) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price HOOKIPA Pharma, Inc.|HOOK - Price Target Chart
- market capitalization data:
Market Value HOOKIPA Pharma|HOOK - Total Company Value
- book capitalization data:
Book Value per Share HOOKIPA Pharma|HOOK - Company Book Value|Market Capitalization to Net Assets hookipapharma.com|HOOK - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio HOOKIPA Pharma Inc.|HOOK - Long-Term Debt to Capital|Short-Term Debt to Capital HOOKIPA Pharma, Inc.|HOOK - Company Debts|Debt to Net Assets Ratio HOOKIPA Pharma|HOOK - Company Long-Term Debt|Company Current Liabilities HOOKIPA Pharma
Comprehensive company analysis:HOOKIPA Pharma Inc. (HOOK)
Original product of HOOKIPA Pharma

For HOOKIPA Pharma Inc. (HOOK), whose value is based on patents in the field of viral vectors, it is critical to track market capitalization in conjunction with debt load. By analyzing the enterprise value, an investor sees the total cost of the business (market cap plus debt minus cash), which allows for an assessment of the real acquisition price of the company at the R&D stage and its financial stability.

Competitor analysis for HOOKIPA Pharma Inc.

argenx N.V. - Total Enterprise Value|BNTX (BioNTech Group) - Total Company Value|ABVX: Total Enterprise Value|ADMA: Total Company Value|PTGX (protagonist-inc.com) - Enterprise Value|Total Company Value Immunovant IMVT|Full Business Value Kiniksa Pharmaceuticals, Ltd.|Grifols Group (GRFS) - Enterprise Value|Value Adjusted for Debt and Cash Adaptive Biotechnologies Inc. (ADPT)|Enterprise Value CLDX (Celldex Therapeutics)|auriniapharma.com - Enterprise Value|Total Company Value BioCryst Pharmaceuticals (BCRX)|VERA: Value Adjusted for Debt and Cash|DNTH (Dianthus Pharma) - Total Company Value|Pharvaris Pharma (PHVS) - Real Price to Acquire Entire Company|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com (TRML)|Precigen (PGEN) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Pharming Group NV (PHAR)|Enterprise Value NKTR|Upstream Pharma - Company Buyout Price|ZBIO: Total Company Value|IMNM: Real Price to Acquire Entire Company|GOSS (Gossamer Bio) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|SEPN (Septerna Corp) - Real Price to Acquire Entire Company|Enterprise Value PVLA|Total Company Value Savara Inc. SVRA|Business Value rigel.com (RIGL)|ANAB: Enterprise Value|Total Enterprise Value Astria Therapeutics Inc ATXS|Enterprise Value enGene Bio (ENGN)|RAPT: Value Adjusted for Debt and Cash|Total Company Value JBIO|ACRS (aclaristx.com) - Total Enterprise Value|Total Company Value KYTX (Kyverna Therapeutics, Inc.)|Total Enterprise Value TLSA|Total Company Value CABA|Enterprise Value Ventyx Biosciences, Inc (VTYX)|Enterprise Value THTX|avalotx.com - Company Buyout Price|Total Company Value Eledon Pharmaceuticals, Inc.|AGEN - Full Business Value|CLYM: Enterprise Value|Enterprise Value Zura Bio Ltd|ATYR - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ADAG|IMA - Total Company Value|Full Business Value shattucklabs.com (STTK)|Enterprise Value Equillium|Value Adjusted for Debt and Cash Connect Biopharma Holdings CNTB|Immunic Inc - Enterprise Value|ATRA: Enterprise Value|Total Company Value inflarx.de IFRX|XFOR (X4 Pharmaceuticals Inc.) - Value Adjusted for Debt and Cash|Total Company Value ACET|Real Price to Acquire Entire Company Celularity Corp|Enterprise Value INMB|Enterprise Value barinthusbio.com BRNS|Real Price to Acquire Entire Company Kezar Life Sciences, Inc.|Value Adjusted for Debt and Cash SAB Biotherapeutics Inc. SABS|Enterprise Value AKTX (Akari Therapeutics plc)|ENLV: Company Buyout Price|Total Company Value q32bio.com|geovax.com (GOVX) - Business Value|Enterprise Value EDSA|Real Price to Acquire Entire Company iBio Inc (IBIO)|CARM (Carisma Therapeutics) - Real Price to Acquire Entire Company|Company Buyout Price XTL Bio (XTLB)|Enterprise Value Bolt Biotherapeutics, Inc.|HCW Biologics, Inc. - Value Adjusted for Debt and Cash|APVO (Aptevo) - Total Company Value|AIM: Total Enterprise Value|Total Company Value ADTX|GRI (GRI Bio Corporation) - Total Enterprise Value|XRTX (XORTX Therapeutics Inc.) - Total Company Value|Enterprise Value HIND|REVB - Total Company Value|Full Business Value Indaptus Therapeutics Inc (INDP)|Enterprise Value Scinai|Value Adjusted for Debt and Cash CalciMedica Inc CALI|Affimed Therapeutics - Enterprise Value|ALLK: Enterprise Value|Total Company Value igmbio.com IGMS|ITOS (iTeos Therapeutics Inc) - Value Adjusted for Debt and Cash|Total Company Value OCEA|Real Price to Acquire Entire Company TC BioPharm Ltd|Enterprise Value THRD